Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

Non-small cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Some recurrent tumors have a comm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kwak, Eunice L., Sordella, Raffaella, Bell, Daphne W., Godin-Heymann, Nadia, Okimoto, Ross A., Brannigan, Brian W., Harris, Patricia L., Driscoll, David R., Fidias, Panos, Lynch, Thomas J., Rabindran, Sridhar K., McGinnis, John P., Wissner, Allan, Sharma, Sreenath V., Isselbacher, Kurt J., Settleman, Jeffrey, Haber, Daniel A.
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2005
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1129023/
https://ncbi.nlm.nih.gov/pubmed/15897464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0502860102
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars